← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cumberland Pharmaceuticals, Inc.
Nashville, TN
$4,950,172
Total funding
9
Grants
Funding over time
peak $2.1M · FY2005–20$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,783,318 · 8
FDA$1,166,854 · 1
By mechanism
R44$1,994,205 · 1
R01$1,166,854 · 1
R41$1,039,970 · 6
R42$749,143 · 1
Investigators at Cumberland Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Targeting DNA damage response pathways for the treatment of advanced lung cancer$1,070,134
R44 · FY2019 · CA
A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)$1,069,742
R01 · FY2019 · FD
Targeting DNA damage response pathways for the treatment of advanced lung cancer$924,071
R44 · FY2018 · CA
TGF-beta for Pleurodesis$492,336
R42 · FY2004 · HL
TGF-beta for Pleurodesis$256,807
R42 · FY2005 · HL
Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation$246,084
R41 · FY2012 · AG
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes$224,999
R41 · FY2016 · DK
Targeting DNA damage response pathways for the treatment of advanced lung cancer$224,910
R41 · FY2014 · ES
Radioprotection by use of Topical Lithium Formulations$121,528
R41 · FY2009 · CA
Mannan, A Potential Therapeutic for Asthma$111,805
R41 · FY2009 · HL
High Purity Amphotericin B: A Safer Antimycotic in AIDS$110,644
R41 · FY2005 · AI
A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)$97,112
R01 · FY2020 · FD